The researchers analyzed more than 3,400 over 20 years old American men without heart disease. Thirty percent of people lack pharmaceutical raw materials vitamin D, which means that each milliliter of blood "sunlight vitamin" levels below 20 nanograms. 16% of people have erectile dysfunction.
The study found that 35 percent of men with vitamin D deficiency
erectile dysfunction, compared with 29% of people do not erectile
dysfunction.
"Vitamin D deficiency is easy to correct by changes in lifestyle,
including proper exercise, dietary changes, vitamin supplements and
moderate sunlight." Said Dr. Erin Michos.
The researchers concluded that with adequate vitamin D levels compared
to people, vitamin D deficiency in men with 32% probability is feeble.
The researchers emphasize
that their findings merely observational study does not prove a causal
relationship, but also the need for more research to determine low
vitamin D levels and erectile dysfunction if there is a direct link. If this is the case, they say it may produce new treatments.
"Check vitamin D levels may be measuring the risk of erectile dysfunction a useful tool," Michos said. "The most relevant clinical question becomes whether the correct
vitamin D deficiency can reduce the risk, to help restore erectile
function."
The
researchers said that about 40 percent of men older than 40 and men
over 70 years of 40% can not achieve and maintain an erection. According
to the Center for Disease Control and Prevention said that vitamin D
deficiency can affect up to 40 percent of adult Americans.
2015年11月17日星期二
The study found men more attractive eating garlic
42
studies were each asked to eat raw garlic or garlic capsules, or do not
eat garlic - when they eat garlic and garlic capsules and appreciate
not eat garlic when compared to men eating garlic odor is considered
"more Attractive".
In this study, 82 women were asked to sniff the smell of the sample and determine whether these men are affable, attractive, or macho.
The researchers found that men eating a lot of garlic will play an unexpected positive effect. When the male eating six grams of garlic, the equivalent of eating two halves with garlic bread and cheese, which they simply eat the bread and cheese is no difference between the ratings.
But when the dose increased to 12 grams of garlic or garlic four petals, which smells than men when they do not eat garlic on more attractive.
In the final experiment, when men consumed in capsule form of the same amount of garlic, their body odor is also considered more attractive.
Psychology professor Craig Roberts said: "Our findings suggest that eating garlic get body odor may be due to its unhealthy give people reasons to produce a feeling of pleasure."
"From an evolutionary perspective, the formation of body odor preferences result diet may be associated with sexual selection. Previous studies have shown that many animal species associated with the use of diet to choose sexual partners in good physical condition."
"Healthy eating garlic features include anti-oxidation, enhance immunity, cardiovascular protection, sterilization and cancer and other functions, which is human odor preference of rational choice."
Study concluded that, unlike the breath odor, garlic output of body odor is very positive, the source of this odor should strictly distinguish between the two.
In this study, 82 women were asked to sniff the smell of the sample and determine whether these men are affable, attractive, or macho.
The researchers found that men eating a lot of garlic will play an unexpected positive effect. When the male eating six grams of garlic, the equivalent of eating two halves with garlic bread and cheese, which they simply eat the bread and cheese is no difference between the ratings.
But when the dose increased to 12 grams of garlic or garlic four petals, which smells than men when they do not eat garlic on more attractive.
In the final experiment, when men consumed in capsule form of the same amount of garlic, their body odor is also considered more attractive.
Psychology professor Craig Roberts said: "Our findings suggest that eating garlic get body odor may be due to its unhealthy give people reasons to produce a feeling of pleasure."
"From an evolutionary perspective, the formation of body odor preferences result diet may be associated with sexual selection. Previous studies have shown that many animal species associated with the use of diet to choose sexual partners in good physical condition."
"Healthy eating garlic features include anti-oxidation, enhance immunity, cardiovascular protection, sterilization and cancer and other functions, which is human odor preference of rational choice."
Study concluded that, unlike the breath odor, garlic output of body odor is very positive, the source of this odor should strictly distinguish between the two.
CRISPR pigs produce human proteins
Human
serum albumin is a protein present in the blood, it can be used to
treat a range of diseases, including liver failure and traumatic shock. Past have tried in pigs produce human serum albumin, but due to
unavoidable produce swine albumin, which makes the separation and
purification of human serum albumin source of great challenge.
Chinese scientists Zhangpu Min and his research team, using the CRISPR / Cas9 gene editing system, the fertilized egg in the pig genome region used to produce pig albumin, insert a paragraph can be synthesized DNA fragments of human albumin. Embedded in the pig genome allele located downstream of pig albumin synthesis genes. The researchers believe that this could make pigs produce human serum albumin, a source at the same time, do not produce swine albumin, serum albumin and so humanized swine albumin mixing can be avoided.
The researchers implanted 300 genomes edited fertilized eggs to 10 sows in vivo, which carry the fertilized eggs are inserted into a human serum albumin alleles. 5 pigs successful pregnancy, birth to 16 piglets Alabama. The researchers found that 16 pigs from a fertilized egg albumin gene that carries a human source, and they can be detected in human blood serum albumin. However, human serum albumin piglets body is different. Further breeding experiments showed that by CRISPR / Cas9 genetic modification tool into the human gene can be passed to the offspring of these piglets.
Chinese scientists Zhangpu Min and his research team, using the CRISPR / Cas9 gene editing system, the fertilized egg in the pig genome region used to produce pig albumin, insert a paragraph can be synthesized DNA fragments of human albumin. Embedded in the pig genome allele located downstream of pig albumin synthesis genes. The researchers believe that this could make pigs produce human serum albumin, a source at the same time, do not produce swine albumin, serum albumin and so humanized swine albumin mixing can be avoided.
The researchers implanted 300 genomes edited fertilized eggs to 10 sows in vivo, which carry the fertilized eggs are inserted into a human serum albumin alleles. 5 pigs successful pregnancy, birth to 16 piglets Alabama. The researchers found that 16 pigs from a fertilized egg albumin gene that carries a human source, and they can be detected in human blood serum albumin. However, human serum albumin piglets body is different. Further breeding experiments showed that by CRISPR / Cas9 genetic modification tool into the human gene can be passed to the offspring of these piglets.
ISIS Pharmaceutical shares fell inexplicably want to rename
This California-based biotechnology company is in charge of the ancient Egyptian goddess Isis fertility and reproduction (ISIS) named, but now most people think that not after seeing ISIS ancient Egyptian goddess.
That is why ISIS Pharmaceuticals to CNN Monday said it is considering amending the company name. The company has not yet made a final decision, did not want to replace what a good name.
Wade Walke, Vice President of the company in charge of Corporate Communications and Investor Relations, said, "While people know that we are nothing to do with terrorists, but the name itself ISIS now there are too many negative energy."
He said the tragedy occurred in Paris gave us "a lot of pressure."
ISIS main production treat cancer, heart disease and nerve disease drugs. The company said last year that no change to modify the company name and "ISIS" ticker.
Although the US stock market yesterday rose, but ISIS share price fell by 4%. The company can not find other reasons can cause stock prices to decline.
That is why ISIS Pharmaceuticals to CNN Monday said it is considering amending the company name. The company has not yet made a final decision, did not want to replace what a good name.
Wade Walke, Vice President of the company in charge of Corporate Communications and Investor Relations, said, "While people know that we are nothing to do with terrorists, but the name itself ISIS now there are too many negative energy."
He said the tragedy occurred in Paris gave us "a lot of pressure."
ISIS main production treat cancer, heart disease and nerve disease drugs. The company said last year that no change to modify the company name and "ISIS" ticker.
Although the US stock market yesterday rose, but ISIS share price fell by 4%. The company can not find other reasons can cause stock prices to decline.
Japanese doctors how to leukemia to "red"
Although,
in the medical conditions of underdevelopment, leukemia are considered
"deadly disease", but the fact that there is a great change. Recently,
Japanese doctors how to Hokkaido, Japan leukemia to "red", Professor of
Hematology University Hospital Fung Tak Nakajima said: "In the past
people's impression of them, leukemia is incurable, but now there are
more than 4 percent of patients can be cured. "
Leukemia, also known as "blood cancer" is a kind of malignant clonal hematopoietic stem cell disorders. Clonal leukemia cells because of uncontrolled proliferation, differentiation disorders, blocked apoptosis and other mechanisms in the bone marrow and other hematopoietic tissues proliferate accumulation and invasion of other tissues and organs, while inhibition of normal hematopoiesis. Clinical seen varying degrees of anemia, bleeding, infection, fever and liver, spleen, lymph nodes and bone pain.
There are many causes of leukemia, there are: 1 viral factors, RNA viruses can cause leukemia. 2. Chemical factors, benzene, nitrosamines, mechlorethamine, cyclophosphamide, procarbazine, VP16, VM26 substances, phenylbutazone and derivatives thereof, chloramphenicol and other chemicals may cause leukemia. 3. Radiation factors, there is evidence that large doses of radiation diagnosis and treatment can increase the incidence of leukemia. 4. genetic factors, chromosomal aberrations have populations higher than normal incidence of leukemia. As people's living environment, viruses, chemical, radioactive and other substances more and more, people are increasingly suffering from leukemia.
What are the symptoms of it had leukemia? Doctors said: "leukemia can cause fever, infection, bleeding, anemia, bone and joint pain, liver and spleen and lymph nodes, central nervous system leukemia, other tissues and organs infiltration and other symptoms."
Because leukemia classification and prognostic stratification complex, so there is no treatment for the monotony, the doctor requires a combination of meticulous typing and prognostic stratification treatment plan. Currently, the Japanese medical community are the following treatment: chemotherapy ﹑ ﹑ radiation therapy targeted therapy, immunotherapy, stem cell transplantation.
However, the emergence of a Japanese medical technology, will bring the gospel of patients with leukemia. According to Japan's NHK television reported that the Japanese RIKEN and other organizations said they had successfully used a specific compound killed cancer stem cells. And this success, it will be possible to make a significant contribution to the fundamental treatment of leukemia.
Each year, about 5,000 people in Japan suffering from acute myeloid leukemia, and if this particular compound, it will be possible the treatment of acute myeloid leukemia relapse rate this fundamentally.
Li Yan, director of the Institute of Chemistry of 石川文 researcher said, "We will be tested repeatedly to ensure that such compounds are effective and safe, and hope to develop as soon as the appropriate drugs for the treatment of patients."
( Bolise Co., Ltd. www.chemicalspharm.com )
Leukemia, also known as "blood cancer" is a kind of malignant clonal hematopoietic stem cell disorders. Clonal leukemia cells because of uncontrolled proliferation, differentiation disorders, blocked apoptosis and other mechanisms in the bone marrow and other hematopoietic tissues proliferate accumulation and invasion of other tissues and organs, while inhibition of normal hematopoiesis. Clinical seen varying degrees of anemia, bleeding, infection, fever and liver, spleen, lymph nodes and bone pain.
There are many causes of leukemia, there are: 1 viral factors, RNA viruses can cause leukemia. 2. Chemical factors, benzene, nitrosamines, mechlorethamine, cyclophosphamide, procarbazine, VP16, VM26 substances, phenylbutazone and derivatives thereof, chloramphenicol and other chemicals may cause leukemia. 3. Radiation factors, there is evidence that large doses of radiation diagnosis and treatment can increase the incidence of leukemia. 4. genetic factors, chromosomal aberrations have populations higher than normal incidence of leukemia. As people's living environment, viruses, chemical, radioactive and other substances more and more, people are increasingly suffering from leukemia.
What are the symptoms of it had leukemia? Doctors said: "leukemia can cause fever, infection, bleeding, anemia, bone and joint pain, liver and spleen and lymph nodes, central nervous system leukemia, other tissues and organs infiltration and other symptoms."
Because leukemia classification and prognostic stratification complex, so there is no treatment for the monotony, the doctor requires a combination of meticulous typing and prognostic stratification treatment plan. Currently, the Japanese medical community are the following treatment: chemotherapy ﹑ ﹑ radiation therapy targeted therapy, immunotherapy, stem cell transplantation.
However, the emergence of a Japanese medical technology, will bring the gospel of patients with leukemia. According to Japan's NHK television reported that the Japanese RIKEN and other organizations said they had successfully used a specific compound killed cancer stem cells. And this success, it will be possible to make a significant contribution to the fundamental treatment of leukemia.
Each year, about 5,000 people in Japan suffering from acute myeloid leukemia, and if this particular compound, it will be possible the treatment of acute myeloid leukemia relapse rate this fundamentally.
Li Yan, director of the Institute of Chemistry of 石川文 researcher said, "We will be tested repeatedly to ensure that such compounds are effective and safe, and hope to develop as soon as the appropriate drugs for the treatment of patients."
( Bolise Co., Ltd. www.chemicalspharm.com )
2015年11月16日星期一
Johnson anti-tumor drug Yondelis heavy granted after a lapse of six years
Drug development is a long process, from pre-clinical to clinical research will experience a considerable period of time. However,
faced with strict examination and approval of the relevant medical
management department, drug development cycle will be longer even in the
foreseeable future. Faced with this situation, many pharmaceutical companies adhere to teeth only select this approval marathon.
Johnson & Johnson recently announced the development of anti-cancer drug Yondelis has been approved by the US FDA for the treatment of soft tissue sarcoma. This marks Yondelis three occasions, approval was finally ended the marathon continued for six years. FDA said that the future Yondelis will be approved for the treatment can not be removed by surgery and chemotherapy liposarcoma and leiomyosarcoma patient tolerance type.
This approval is based on the latest phase III clinical study results submitted by Johnson & Johnson. In this there are 518 patients involved in the study, compared to conventional chemotherapy dacarbazine, Yondelis can significantly prolong the survival of patients.
For Johnson & Johnson, the approval of Yondelis is undoubtedly the end of a painful journey.
In 2001, Johnson & Johnson is obtained from the Spanish pharmaceutical company Zeltia authorization of this drug, and began Yondelis in ovarian cancer. In 2009, FDA because of security problems and the effect is not too significant and other reasons rejected the listing application Yondelis and Doxil combination therapy. Two years later the same reason, Johnson was forced to suspend the project and turn malignant sarcoma research and development.
Earlier, at Zeltia companies and other partners efforts, Yondelis has been successfully listed on the world's countries and regions. And after a lapse of six years, Yondelis is approved in the US market is undoubtedly an important supplement to the drug market. After a marathon six years, holding exclusive rights to sell Yondelis US market will probably sigh of Johnson & Johnson.
Johnson & Johnson said that soft tissue sarcoma is a rare malignant tumor, about five thousand people die each year of diseases. The two approved indications Yondelis is a higher degree of malignancy of this tumor type.
(Bolise Co., Ltd. www.chemicalspharm.com)
Johnson & Johnson recently announced the development of anti-cancer drug Yondelis has been approved by the US FDA for the treatment of soft tissue sarcoma. This marks Yondelis three occasions, approval was finally ended the marathon continued for six years. FDA said that the future Yondelis will be approved for the treatment can not be removed by surgery and chemotherapy liposarcoma and leiomyosarcoma patient tolerance type.
This approval is based on the latest phase III clinical study results submitted by Johnson & Johnson. In this there are 518 patients involved in the study, compared to conventional chemotherapy dacarbazine, Yondelis can significantly prolong the survival of patients.
For Johnson & Johnson, the approval of Yondelis is undoubtedly the end of a painful journey.
In 2001, Johnson & Johnson is obtained from the Spanish pharmaceutical company Zeltia authorization of this drug, and began Yondelis in ovarian cancer. In 2009, FDA because of security problems and the effect is not too significant and other reasons rejected the listing application Yondelis and Doxil combination therapy. Two years later the same reason, Johnson was forced to suspend the project and turn malignant sarcoma research and development.
Earlier, at Zeltia companies and other partners efforts, Yondelis has been successfully listed on the world's countries and regions. And after a lapse of six years, Yondelis is approved in the US market is undoubtedly an important supplement to the drug market. After a marathon six years, holding exclusive rights to sell Yondelis US market will probably sigh of Johnson & Johnson.
Johnson & Johnson said that soft tissue sarcoma is a rare malignant tumor, about five thousand people die each year of diseases. The two approved indications Yondelis is a higher degree of malignancy of this tumor type.
(Bolise Co., Ltd. www.chemicalspharm.com)
Type 2 diabetes drug can significantly reduce hospitalization for heart failure and lead to death
Recently, a new study published in international academic journals
NEJM first to suggest a type 2 diabetes drug can significantly reduce
hospitalizations for heart failure and lead to death.
The findings come from a known EMPA-REG OURCOME of large clinical trials, from Yale University, Dr. Silvio E. Inzucchi held in Orlando in 2015 the American Heart Association scientific meetings about the progress of this research.
Many patients with type 2 diabetes are also at the same time the presence of heart failure, the heart they can not effectively pump blood into the circulation system. The current treatment of treatment of heart failure is very limited, but some studies have found no previous treatment of type 2 diabetes in heart failure have a therapeutic effect. But an increase in the blood glucose is discharged through urine by new therapeutic drugs to achieve glycemic control (SGLT2 inhibitors) has not been studied.
In this EMPA-REG experiments, researchers will have type 2 diabetes in patients with heart disease risk while randomized, to some patients taking a new antidiabetic drugs --empagliflozin (10mg or 25mg dose) each day, as well as Some patients taking placebo. Drug and placebo are administered in addition to standard treatment.
To the end of the experiment, the researchers found that compared with patients taking placebo, patients taking the drug blood sugar and blood pressure declined, while weight also declined. They also found that patients taking the drug died of heart disease, the proportion declined significantly; the proportion of hospitalizations due to heart failure also appears significantly decreased; the proportion of deaths from any cause was also significantly decreased.
In addition, Inzucchi and colleagues there and the absence of heart failure, heart failure patients with type 2 diabetes start of the test carried out further analysis showed that the ratio of these two groups of patients had decrease in hospitalizations are similar, So they come to a conclusion, empagliflozin already suffering not only to prevent further deterioration in patients with heart failure, but also not suffering from heart failure can help prevent heart failure in patients with diabetes.
August 2014 Boehringer Ingelheim - Lilly Diabetes Federation announced, diabetes DRUG Jardiance (empagliflozin) approved by the FDA, combined with diet and exercise for adult patients with type 2 diabetes therapy to improve blood sugar control.
The findings come from a known EMPA-REG OURCOME of large clinical trials, from Yale University, Dr. Silvio E. Inzucchi held in Orlando in 2015 the American Heart Association scientific meetings about the progress of this research.
Many patients with type 2 diabetes are also at the same time the presence of heart failure, the heart they can not effectively pump blood into the circulation system. The current treatment of treatment of heart failure is very limited, but some studies have found no previous treatment of type 2 diabetes in heart failure have a therapeutic effect. But an increase in the blood glucose is discharged through urine by new therapeutic drugs to achieve glycemic control (SGLT2 inhibitors) has not been studied.
In this EMPA-REG experiments, researchers will have type 2 diabetes in patients with heart disease risk while randomized, to some patients taking a new antidiabetic drugs --empagliflozin (10mg or 25mg dose) each day, as well as Some patients taking placebo. Drug and placebo are administered in addition to standard treatment.
To the end of the experiment, the researchers found that compared with patients taking placebo, patients taking the drug blood sugar and blood pressure declined, while weight also declined. They also found that patients taking the drug died of heart disease, the proportion declined significantly; the proportion of hospitalizations due to heart failure also appears significantly decreased; the proportion of deaths from any cause was also significantly decreased.
In addition, Inzucchi and colleagues there and the absence of heart failure, heart failure patients with type 2 diabetes start of the test carried out further analysis showed that the ratio of these two groups of patients had decrease in hospitalizations are similar, So they come to a conclusion, empagliflozin already suffering not only to prevent further deterioration in patients with heart failure, but also not suffering from heart failure can help prevent heart failure in patients with diabetes.
August 2014 Boehringer Ingelheim - Lilly Diabetes Federation announced, diabetes DRUG Jardiance (empagliflozin) approved by the FDA, combined with diet and exercise for adult patients with type 2 diabetes therapy to improve blood sugar control.
订阅：
博文 (Atom)